RealFeedApp OTCD treatment candidate OTXL-101 receives in-license deal
The Orphan Therapeutics Accelerator (OTXL) has in-licensed an investigational therapy program for ornithine transcarbamylase deficiency (OTCD), now named OTXL-101. This marks the first therapy in-licensed by the nonprofit biotech.
- Field
- gene therapy
- What they did
- Orphan Therapeutics Accelerator (OTXL) has licensed its first gene therapy program to treat ornithine transcarbamylase deficiency (OTCD), a rare genetic disorder causing toxic substance buildup in the body.
- Why it matters
- This enables the development of a previously shelved drug by leveraging tax incentives and nonprofit support to accelerate its commercialization.
#gene therapy#rare disease#in-license#otxl
